Transcriptomics

Dataset Information

0

Histologic transformation induced by EGFR tyrosine kinase inhibitors


ABSTRACT: Although tyrosine kinase inhibitors (TKIs) targeting Epidermal Growth Factor Receptor (EGFR) activating mutations have significantly improved outcomes in EGFR-mutant non-small cell lung cancer, resistance inevitably develops. Despite the heterogeneity of resistance mechanisms, many induce activation of MAPK signaling in the presence of EGFR-TKIs. ARAF gene amplification is identified as one such mechanism that activates MAPK signaling by directly interacting with RAS, yet its clinicopathologic characteristics remain poorly understood. We characterized five cases with ARAF amplification resistant to first- or second-generation EGFR-TKIs and screened an additional 48 re-biopsied specimens following resistance to Osimertinib. Among Osimertinib-resistant tumors, we identified four cases with ARAF amplification. Overall, these nine ARAF-amplified resistant tumors retained their original founder EGFR mutation and lacked secondary alterations. Furthermore, we identified two cases showing histologic transformation from lung adenocarcinoma to small cell lung cancer (SCLC). SCLC can be classified into four subtypes defined by transcriptional signatures driven by specific transcription factors. To estimate the subtypes of these resistant tumors, RNA sequencing analysis was performed in paired samples before and after treatment with EGFR-TKIs.

ORGANISM(S): Homo sapiens

PROVIDER: GSE274293 | GEO | 2024/10/30

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-03-11 | PXD020108 | Pride
2021-08-27 | GSE168280 | GEO
2021-04-28 | GSE163913 | GEO
2024-09-02 | BIOMD0000000827 | BioModels
2018-01-11 | GSE103352 | GEO
2015-01-30 | E-GEOD-64765 | biostudies-arrayexpress
2016-03-29 | E-GEOD-79688 | biostudies-arrayexpress
2022-04-06 | GSE193256 | GEO
2022-04-06 | GSE193258 | GEO
2022-04-06 | GSE193257 | GEO